The use of the antiepileptic drug valproic acid (VPA) as a histone deacetylase inhibitor with antitumor activities has limitations. Treatment of four human neuroblastoma cell lines with VPA increased CD133 expression and displayed higher proliferation of cells with lower sensitivity to cytostatic treatment. The gene discussed is PROM1; the disease is neuroblastoma.